{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings",
  "queries": [
    "https://consensus.app/search/shingles-vaccination-dementia-prevention/xhVN6XsBTRChSpDDuP6I3g/"
  ],
  "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.",
  "primary_comparison_count": 9,
  "primary_comparisons": [
    {
      "pmid": "40175543",
      "doi": "10.1038/s41586-025-08800-x",
      "source_type": "primary study report",
      "study_group": "Welsh_eligibility_SAIL",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Consensus groups natural experiments as1.8–3.5percentage-point reductions after vaccine eligibility.",
      "result_comparison": "The original Welsh body distinguishes eligibility from receipt:3.5points is the fuzzy CACE receipt estimate. It uses a local complier counterfactual-risk construction and not a simple division of the overall control risk. Diagnosis sources and lack of primary competing-death adjustment are explicit.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/40175543/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\examinations\\original-0-10-3000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\body-presentation-receipts\\40175543-s6-p4-8-10-12.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\body-presentation-receipts\\40175543-s8-p6-7-8-12-14-15.json"
      ]
    },
    {
      "pmid": "41579903",
      "doi": "10.1016/S1474-4422(25)00455-7",
      "source_type": "primary study report",
      "study_group": "Canadian_CPCSSN_CHSS",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Consensus describes Ontario2.0point diagnosis reduction and female-predominant protection.",
      "result_comparison": "Selected original Methods/Results confirm the eligibility estimand, uptake from a separate CHSS survey, primary27.4point first stage with lowerCI0.0 and secondary13.9point interval crossing zero. Women-significant/men-nonsignificant has interactionP=.218; this cannot establish a verified sex boundary.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/41579903/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\examinations\\original-0-10-3000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\body-presentation-receipts\\41579903-s1-p2-4-5.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\body-presentation-receipts\\41579903-s2-p1-3-5-7.json"
      ]
    },
    {
      "pmid": "39053634",
      "doi": "10.1038/s41591-024-03201-5",
      "source_type": "primary study report",
      "study_group": "PMID39053634",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus says recombinant vaccination is associated with17%delay and164days.",
      "result_comparison": "The original reports17%increase in diagnosis-free time, with164days among participants subsequently diagnosed, not17%relative risk reduction in all recipients. Calendar transition and active vaccine matching remain observational limitations.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/39053634/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\examinations\\original-10-20-3000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "42754179",
      "doi": "10.1016/j.bbi.2026.107021",
      "source_type": "primary study report",
      "study_group": "PMID42754179",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus includes the2026 critique of implausibly large implied vaccine effectiveness, labelling its claim weak.",
      "result_comparison": "The original new quantitative secondary analysis reports18%Wales,177%Australia and84%/111%Canada under its published-estimate scaling. These are analytical estimates rather than new vaccine trials. Their denominator/complier-risk assumptions require reconciliation with the Welsh local CACE method; provider strength labels do not adjudicate the critique.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/42754179/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\examinations\\original-10-20-3000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "42296498",
      "doi": "10.7326/ANNALS-25-04689",
      "source_type": "primary study report",
      "study_group": "PMID42296498",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus says recombinant vaccination lowered nursing-home four-year dementia incidence by about5.8points.",
      "result_comparison": "The original reports an association in a clone-censor-weight emulation, with negative controls suggesting residual confounding. Only1.73%received vaccine and87%of these did so after discharge; wording is qualified to association rather than proven lowering.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/42296498/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\examinations\\original-0-10-3000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "40562756",
      "doi": "10.1038/s41541-025-01172-3",
      "source_type": "primary study report",
      "study_group": "PMID40562756",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus interprets similar AS01-adjuvanted RSV/zoster protection as an adjuvant-specific mechanism.",
      "result_comparison": "The original is a matched observational comparison with no significant product difference. Nonsignificance is not equivalence, and sharing an adjuvant is not a randomized adjuvant-versus-virus dissociation; the mechanism remains a hypothesis.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/40562756/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\examinations\\original-20-30-2800.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "35170873",
      "doi": "10.1002/acn3.51525",
      "source_type": "primary study report",
      "study_group": "PMID35170873",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus contrasts VZV-suppression and immune explanations but emphasizes positive reactivation/antiviral links.",
      "result_comparison": "The original UK cohort reports no increased dementia after overt HZ, no dementia-or-death association, and no antiviral prescription variation. This important challenge is retained alongside positive registry studies and does not itself exclude subclinical viral effects.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/35170873/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\examinations\\original-0-10-3000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "40258956",
      "doi": "10.1038/s41591-025-03616-8",
      "source_type": "primary study report",
      "study_group": "PMID40258956",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Consensus says other preventive drugs do not produce broad class effects, without supplying the named randomized hypertension result.",
      "result_comparison": "The original326-village randomized care programme significantly lowers all-cause dementia over48months. This genuine clinical prevention positive is preserved for its exact package, alongside SPRINT dementia-null/MCI-positive and aspirin/HYVET nulls; it neither validates nor refutes vaccination.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/40258956/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\examinations\\original-40-50-3000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "40175543",
      "doi": "10.1038/s41586-025-08800-x",
      "source_type": "primary study report",
      "study_group": "Welsh_eligibility_SAIL",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Consensus discovers an English regression-discontinuity study with shingles reduction and dementia null.",
      "result_comparison": "The original medRxiv repository abstract was independently read: Hamilton etal2026 doi10.64898/2026.07.20.26358345v1 is explicitly unreviewed. It reports hospital-dementia eligibility RD−.06points,CI−.40to.27,P=.72, including Welsh ascertainment comparisons. It is retained as a separate non-counted preprint challenge, with no invented original Methods reading or inclusion among53peer-reviewed reports.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/40175543/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\examinations\\original-0-10-3000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\body-presentation-receipts\\40175543-s6-p4-8-10-12.json",
        "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\body-presentation-receipts\\40175543-s8-p6-7-8-12-14-15.json"
      ]
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\shingles-vaccination-dementia\\consensus-browser-2026-10-13.json",
      "sha256": "288b10c22e7defd7108d2d1819d69bf5d7293546049673a569992a57a5610f05"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-13",
  "completed_utc": "2026-10-13T17:35:23.337103+00:00",
  "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
}